Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.

Journal of thrombosis and haemostasis : JTH - 1 Sept 2014

Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G

Abstract excerpt

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy characterized by hemolysis, platelet consumption, and renal injury. Eculizumab, a mAb that blocks complement activity, has been successfully used in aHUS. OBJECTIVES: To optimize eculizumab therapy in aHUS patients by monitoring complement functional tests and markers of disease activity. PATIENTS/METHODS: We studied 18 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Atypical Hemolytic Uremic Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement C3

Share to Complement C5

Share to Complement Factor H

Share to Hemolysis

Share to Platelet Count

Share to Remission Induction

Source

Identifiers

PMID: 24853860
DOI: 10.1111/jth.12615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.PMID 24853860Read ↗

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.Semantic proximity Read ↗

Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy.Semantic proximity Read ↗

Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeSemantic proximity Read ↗

Consensus regarding diagnosis and management of atypical hemolytic uremic syndromeSemantic proximity Read ↗

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUSSemantic proximity Read ↗

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.Semantic proximity Read ↗

How I diagnose and treat atypical hemolytic uremic syndromeSemantic proximity Read ↗

Atypical Hemolytic Uremic SyndromeSemantic proximity Read ↗

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)Semantic proximity Read ↗

Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.Semantic proximity Read ↗

An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus documentSemantic proximity Read ↗

[Atypical hemolytic uremic syndrome].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.